Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase I/II trial designed
to characterize the safety and estimate the efficacy of nintedanib when combined with
paclitaxel chemotherapy compared with paclitaxel chemotherapy alone in patients with BRAF
wild type metastatic melanoma not previously treated with taxanes or kinase inhibitors.